Skip to content

CEO interview. Annual Report 2025.

A record year.

Gubra’s Annual Report for 2025 marks a record-breaking year, with group revenue reaching DKK 2.6 billion and operating profit at DKK 2.2 billion. We have achieved significant milestones in our R&D pipeline, highlighted by the ABBV295 deal with AbbVie and promising progress on first-in-class assets. Our lead candidate for high-quality weight loss, GUB-UCN2, is on track to enter clinical development in the first half of 2026.

We invite you to read the full press release and to watch this interview with Markus Rohrwild where he shares his reflections on the remarkable year for Gubra and his vision for the future.

Share this page

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

[email protected]
+45 3152 ­2650

Back To Top